Simont Braun assists the European Commission against AstraZeneca
Estimated time to read this article2 min
Date of publication28 April 2021
Author(s)Paul Alain Foriers, Rafaël Jafferali, Charles-Edouard Lambert, Fanny Laune, Marie Nelles
Simont Braun is proud to represent the European Commission and the 27 Member States in the judicial proceedings against AstraZeneca for the delays in supplying millions of Covid-19 vaccine doses.
The action is based on the breach of the contract terms and the lack of a reliable strategy by AstraZeneca to timely ensure the delivery of vaccines in the framework of the Covid-19 crisis.
The action seeks for preliminary injunctions in emergency proceedings, in parallel with a claim on the merits. The main goal of the action is to speed up the production and delivery of vaccines to the Member States.
The introductory hearing took place this morning before the President of the French-speaking Brussels Court of First Instance. These preliminary proceedings will be treated according to an accelerated timetable.
“We are proud to have been selected to assist the European Commission in this challenging matter,” says Rafaël Jafferali, partner in Dispute Resolution. “This is a crucial case for the entire European Union, and these proceedings will have a significant societal, health and economic impact.”
The European Commission acts on its behalf and on behalf of the 27 Member States.
The Simont Braun team which advises the European Commission is led by partners Paul Alain Foriers and Rafaël Jafferali, with the assistance of Fanny Laune (Counsel), Charles-Edouard Lambert and Marie Nelles (associates).
More information on the European Commission’s statements available in The New York Times.
Contact: Rafaël Jafferali – email@example.com